Curidium Lands $5M in Share Offering, Plans to Push Mental Health Dx | GenomeWeb
NEW YORK (GenomeWeb News) - Curidium Medica said today that it has grossed £2.5 million ($5.1 million) through the sale of 100 million shares at a price of 2.5 pence per share.
The London-based company said it plans to use the proceeds from the stock sale to fund product and business development programs. Part of the new capital will feed new R&D and business development programs for Curidium’s PsychINDx test, a blood-based diagnostic that categorizes patients with schizophrenia/bipolar disorder into four subgroups.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.